Analysed JAGUAR HEALTH INC (JAGX:NASDAQ) News Sources
Jaguar Health Expands Neonorm Franchise with Introduction of Neonorm Dog for Companion Animal Gut Health
04-05-2026
yahoo.com
Jaguar Health Announces Preliminary Discussion with FDA to Evaluate Breakthrough Therapy Designation for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID)
06-05-2026
yahoo.com
Jaguar Health Regains Compliance with Nasdaq's Publicly Held Shares Requirement and Receives Additional Extension, Until May 18, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule
08-05-2026
yahoo.com
Jaguar Health Announces Active Treatment Only Continuation of Pivotal Multicenter Clinical Trial in Pediatric Patients with Microvillus Inclusion Disease (MVID) to Support a New Drug Application (NDA) for Liquid Oral Crofelemer
19-05-2026
yahoo.com
Jaguar Health to Hold Investor Webcast May 26 Regarding Q1 2026 Financials & Corporate Updates; Jaguar CEO Lisa Conte Presenting May 28 at Lytham Partners Spring 2026 Investor Conference
20-05-2026
yahoo.com
Jaguar Health Inc (JAGX) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic ...
26-05-2026
yahoo.com
What is the current price of JAGUAR HEALTH INC (JAGX:NASDAQ)?
The current price of JAGUAR HEALTH INC (JAGX:NASDAQ) is $3.19.
JAGUAR HEALTH INC (JAGX:NASDAQ) absolute price change since previous trading day?
The absolute price change of JAGUAR HEALTH INC (JAGX:NASDAQ) since the previous trading day is $0.
JAGUAR HEALTH INC (JAGX:NASDAQ) percentage price change since previous trading day?
The percentage price change of JAGUAR HEALTH INC (JAGX:NASDAQ) since the previous trading day is 0%.
What is the most recent average sentiment score for JAGUAR HEALTH INC (JAGX:NASDAQ)?
The most recent average sentiment score for JAGUAR HEALTH INC (JAGX:NASDAQ) is 64 out of 100.
What is the most recent average sentiment for JAGUAR HEALTH INC (JAGX:NASDAQ)?
The most recent sentiment for JAGUAR HEALTH INC (JAGX:NASDAQ) is .
SEC-8K** Filing Available For JAGUAR HEALTH INC (JAGX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.